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AbstrAct
background Hereditary myopathy with lactic 
acidosis and myopathy with deficiency of succinate 
dehydrogenase and aconitase are variants of a 
recessive disorder characterised by childhood-onset 
early fatigue, dyspnoea and palpitations on trivial 
exercise. The disease is non-progressive, but life-
threatening episodes of widespread weakness, 
metabolic acidosis and rhabdomyolysis may occur. So 
far, this disease has been molecularly defined only in 
Swedish patients, all homozygous for a deep intronic 
splicing affecting mutation in ISCU encoding a scaffold 
protein for the assembly of iron–sulfur (Fe-S) clusters. 
A single Scandinavian family was identified with a 
different mutation, a missense change in compound 
heterozygosity with the common intronic mutation. The 
aim of the study was to identify the genetic defect in our 
proband.
Methods A next-generation sequencing (NGS) 
approach was carried out on an Italian male who 
presented in childhood with ptosis, severe muscle 
weakness and exercise intolerance. His disease was 
slowly progressive, with partial recovery between 
episodes. Patient’s specimens and yeast models were 
investigated.
results Histochemical and biochemical analyses 
on muscle biopsy showed multiple defects affecting 
mitochondrial respiratory chain complexes. We identified 
a single heterozygous mutation p.Gly96Val in ISCU, 
which was absent in DNA from his parents indicating 
a possible de novo dominant effect in the patient. 
Patient fibroblasts showed normal levels of ISCU protein 
and a few variably affected Fe-S cluster-dependent 
enzymes. Yeast studies confirmed both pathogenicity and 
dominance of the identified missense mutation.
conclusion We describe the first heterozygous 
dominant mutation in ISCU which results in a phenotype 
reminiscent of the recessive disease previously reported.
IntroductIon
Iron–sulfur (Fe-S) clusters are prosthetic groups 
found in several mitochondrial, cytosolic and 
nuclear enzymes, which play a role in funda-
mental cellular processes, such as respiration, DNA 
synthesis and repair, ribosome biogenesis and iron 
metabolism. In eukaryotes, the biogenesis of Fe-S 
clusters is performed by two main multiprotein 
machineries, the ISC (iron–sulfur cluster assembly) 
machinery localised in mitochondria and the CIA 
(cytosolic iron–sulfur protein assembly) machinery 
localised in the cytosol.1 2 Fe-S clusters are found in 
almost all living organisms, and the most common 
stoichiometric species include [2Fe-2S], [3Fe-4S] 
and [4Fe-4S] structures in which the Fe ions are 
co-ordinated, for example, by cysteine thiol groups 
or histidine residues.
The ISC machinery is involved in the biogenesis 
of Fe-S proteins in mitochondria enzymes as well 
as in the cytosol and nucleus. The current under-
standing of the molecular mechanism of mitochon-
drial Fe-S protein biogenesis has been worked out 
in both yeast and human cells. The ISC machinery 
comprises 18 known proteins that perform several 
steps of Fe-S cluster synthesis, transfer and insertion 
into recipient proteins including subunits of the 
mitochondrial respiratory chain (MRC) complexes 
I, II and III, mitochondrial aconitase (mACO) and 
lipoic acid synthase (LIAS).3 De novo synthesis of 
the [2Fe-2S] cluster is accomplished on the scaffold 
protein ISCU. This reaction requires the cysteine 
desulfurase NFS1 with its stabilising partners ISD11/
LYRM4 and ACP1, frataxin/FXN as an iron donor 
and/or regulator of cysteine desulfurase activity, 
and the ferredoxin FDX2 (MIM 614585) as an 
electron donor for sulfur reduction.4 5 Conflicting 
results have been published regarding the role of 
FDX1 (MIM 103260) in this process.6 7 All these 
ISC proteins form a dynamic complex with ISCU. 
Dissociation of the preformed Fe-S cluster from 
the ISCU scaffold and transfer to intermediate 
carriers, for example the monothiol glutaredoxin 
GLRX5 (MIM 609588), is mediated by a dedi-
cated Hsp70-Hsp40 chaperone system (HSC20/
HSP70).8 The transiently GLRX5-bound [2Fe-2S] 
cluster is inserted into [2Fe-2S] targets or used for 
[4Fe-4S] cluster synthesis by ISCA1-ISCA2-IBA57. 
Finally, the cluster is inserted into target apopro-
teins with the help of factors including IND1 (MIM 
613621), NFU1 (MIM 608100) and BOLA3 (MIM 
613183). A different targeting mode has been 
suggested, based on interactions of the adaptable 
HSC20/HSPA9 scaffold complex with LYR motifs 
of SDHAF1 for complex II,9 with LYRM7 for 
complex III or directly with Fe-S cluster subunits 
of complex I.10
Recessive mutations in ISCU have been described 
in patients presenting myopathy with severe 
exercise intolerance and myoglobinuria (MIM 
255125). A homozygous intronic transversion 
(c.418+382G>C or IVS5 +382G>C) was initially 
reported in patients from northern Sweden, with 
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associated deficiencies of succinate dehydrogenase and aconitase 
in skeletal muscle.11 12 The mutation causes the retention of an 
‘extra exon’, leading to marked reduction of ISCU mRNA and 
protein in patient muscle. The splicing defect was shown to be 
selective for muscle tissue, thus explaining the muscle-specific 
phenotype of this disorder.13 Later, compound heterozygosity 
for the common intronic mutation and a missense c.149G>A/p.
G50E substitution was found in two brothers with Swedish/
Finnish origin. These boys had a more severe phenotype than 
patients homozygous for the intronic mutation, with progres-
sive and severe muscle weakness, muscle wasting and heart 
involvement.14
Contrary to the muscular phenotype of ISCU mutant patients, 
mutations in other components of the core Fe-S assembly 
complex cause neurological diseases (eg, Friedreich’s ataxia, 
MIM 229300, due to FXN mutations) or multisystem disorders 
(eg, combined oxidative phosphorylation deficiency 19, MIM 
615595, due to ISD11/LYRM4 mutations).
We report here a patient with myopathy, lactic acidosis and 
combined MRC complex deficiency, caused by a de novo hetero-
zygous missense pathological variant in ISCU.
Methods
histochemical and biochemical studies in skeletal muscle
Muscle morphology and histochemistry, respiratory chain 
activities of complexes I to IV and pyruvate dehydroge-
nase complex (PDHC) assays were performed as previously 
described.15–17 Histochemical staining of iron using Prussian blue 
colour was performed as previously described.18
Genetic analysis
Genomic DNA was extracted from peripheral blood by stan-
dard methods. Whole exome sequencing (WES) and variants 
filtering were performed as previously described.19 Variants 
identified by WES were validated by Sanger sequencing. For 
deep sequencing of parental DNAs, the PCR products were 
processed with Nextera XT DNA sample preparation kit 
(Illumina). Sequencing was performed on an Illumina MiSeq 
instrument.
RNA was extracted from skin fibroblasts, and 1 µg was used 
as template for RT-PCR to obtain full-length cDNA. ISCU tran-
script was amplified by PCR and run through a 1% agarose gel in 
order to detect potential splicing alterations. PCR products were 
also sequenced in order to confirm genomic variants and unmask 
potential events of nonsense-mediated decay.
cell culture and biochemical analysis of fibroblast samples
Fibroblasts obtained from skin biopsy were grown in 1 g/L 
glucose DMEM-F14 (Euroclone) supplemented with 20% fetal 
bovine serum (FBS), 1% uridine, 1% L-glutamine and 0.2% 
sodium pyruvate.
For enzyme activity measurements, cells were treated with 
digitonin in order to separate a cytosolic cell fraction from a 
crude mitochondria-containing organellar fraction.20 Biochem-
ical assays were essentially performed as described.16 Analysis 
of steady-state protein levels by immunoblotting was carried out 
by common methods, using a 6%–20% sodium dodecyl sulfate 
polyacrylamide (SDS-PA) gradient gel. Blocked membranes were 
probed with primary antibodies (online supplementary table 
S1), and antigens were visualised by horseradish peroxidase 
(HRP) coupled secondary reagents and a chemiluminescence 
reaction.
Yeast studies
Details on yeast strains, media, cloning procedures and vectors21 22 
as well as on generation of mutant allele and construction of 
mutant strains23–25 are reported in the online supplementary data
Complex II (succinate dehydrogenase (SDH)) and complex IV 
(cytochrome c oxidase (COX)) specific activities were measured 
on a mitochondrial-enriched fraction prepared as previously 
described.26 27 Aconitase activity was measured in whole-cell 
extracts.28 In vivo radiolabelling of yeast cells with 55FeCl3 (ICN) 
and measurement of 55Fe-incorporation into Fe-S proteins by 
immunoprecipitation and scintillation counting were performed 
as described.29 Antibodies against c-Myc were obtained from 
Santa-Cruz. The green fluorescent protein (GFP) based reporter 
assay for determination of FET3 promoter strength was described 
previously.29 The iron content was determined by a colorimetric 
assay, essentially as described before.30 31
bioinformatics and structural analysis tools
The effect of the p.(Gly96Val) substitution on ISCU function 
was predicted using the in silico tools (ie, SIFT, Polyphen2 and 
EVmutation), all running recommended parameters. All images 
of the Escherichia coli IscU-IscS (PDB ID:3LVL) complex were 
made by using Visual Molecular Dynamics viewer.32 The eval-
uation of the impact of the mutated residue and the protein–
protein interaction analysis were performed by using Swiss PDB 
viewer,33 and FirstGlance in Jmol (http://www. jmol. org)
results
case report
The patient is a 23-year-old Italian male, first child from non-con-
sanguineous parents, born at term after a normal pregnancy by 
caesarean delivery. He has a healthy younger brother. He started 
walking at 18 months, but he always presented some walking 
difficulties, with frequent falls. Parents reported easy fatigability 
since the first years of life. At 7 years of age, the neurological 
examination showed bilateral ptosis not associated with ophthal-
moparesis, muscle hypotonia and wasting, and absent deep 
tendon reflexes. No obvious weakness was present, but marked 
exercise intolerance was reported. Neither cognitive impair-
ment nor other central nervous system (CNS) involvements 
were noticed. The brain nuclear magnetic resonance (NMR) 
and the EEG were normal. Electromyography showed myopa-
thic changes in all tested muscles. Creatine kinase (CK) level was 
slightly increased (about 300 U/L; normal values, n.v.:<180), 
lactate acid was high in blood (4.6 mmol/L; n.v.: 0.4–2.2). He 
showed leucopenia (2.94×103/µL; n.v.: 5–14) and anaemia 
(haemoglobin 10.9 g/dL; n.v. 13–16) with microcythemia (72.9; 
n.v. 80–99); a bone marrow biopsy performed at 7 years was 
normal. No heart involvement was present: echocardiogram and 
ECG were both normal. Over time, his clinical conditions wors-
ened and he started presenting episodes of profound exercise 
intolerance and weakness, with partial recovery of muscle weak-
ness between episodes in about 2 weeks. During these episodes, 
the patient was unable to walk, and showed tachycardia; neither 
breathing shortness nor dysphagia was noticed. At the neurolog-
ical examination at 17 years of age, he presented predominantly 
distal limb weakness with muscle hypotrophy; deep tendon 
reflexes were absent. He was able to stand up from a chair and 
walk, but was unable to run. No signs of CNS involvement were 
present; CK level remained high (about 1700 U/L). The disease 
has since been slowly progressive, punctuated by episodes of 
acute weakness, with preserved cognitive function and no other 
signs of CNS involvement.
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histochemical and biochemical analyses in skeletal muscle
A first muscle biopsy was performed at 8 years of age. At the histo-
logical examination, fibre size variability was present. The main 
feature was a severe reduction of the histochemical reaction for 
both COX and SDH, not associated with ragged red fibres. The 
biochemical examination showed severe decrease of all the MRC 
complexes (I, II, III, IV), with strong increase in citrate synthase 
(CS) activity (online supplementary figure S1A). A second muscle 
biopsy was performed at 22 years, confirming the histological and 
histochemical findings (figure 1A-C). At this age, the reduction 
in the MRC complex activities was still present, yet normal CS 
activity was observed (online supplementary figure S1B). Further-
more, the activity of PDHC was reduced (PDH/CS: 1.8, normal 
values: 2.5–5.0). After the genetic identification of the ISCU variant 
(see below), we carried out histological analysis for the presence 
of iron deposits in the muscle biopsy by Perls staining. We found 
Perls-positive material in numerous patient’s fibres, whereas no 
such material was detected in control muscle biopsies, indicating 
iron overload in ISCU-mutant muscle (figure 1D).
Genetic studies
Genetic alterations linked to mitochondrial DNA were ruled 
out: no mutation was detected by sequencing and no evidence of 
depletion or deletion was observed by Southern blot analysis of 
mitochondrial DNA from muscle. We performed WES on genomic 
DNA from the proband. After filtering steps to exclude common 
SNPs (frequency >0.5%), we selected genes with two compound 
heterozygous or one homozygous variant, according to a predicted 
recessive mode of inheritance. Then we focused on genes encoding 
proteins with mitochondrial localisation. Two entries were found: 
MTIF2 (translation initiation factor IF-2, mitochondrial) and 
PDPR (pyruvate dehydrogenase phosphatase regulatory subunit). 
However, the two missense variants in MTIF2 were in cis, on the 
same paternal allele, whereas the two variants in PDPR were not 
confirmed by Sanger sequencing, being probably due to the pres-
ence of a pseudogene. No hemizygous variant, suggestive of an 
X-linked transmission, was detected. A deep analysis of the hetero-
zygous variants, prioritising genes associated with mitochondrial 
myopathies, highlighted a single variant in ISCU, a c.287G>T 
(NM_213595.2) predicted to cause the amino acid substitution 
p.G96V (figure 2A). This nucleotide change was not reported in 
public variant databases (dbSNP, EVS, ExAC (August 2016)); the 
substitution affected a highly conserved residue (figure 2B) and gave 
high scores of pathogenicity, according to several bioinformatics 
tools. This variant was confirmed by Sanger sequencing in the 
proband but was not present in the parents’ blood DNA, indicating 
Figure 1 Histochemical analysis of the patient’s muscle biopsy. (A) Gomori trichrome stain showing fibre size variability. (B) Strongly reduced 
histochemical activity of succinate dehydrogenase. Few fibres showed succinate dehydrogenase-positive staining (arrows). (C) Cytochrome c oxidase (COX) 
staining showing scattered fibres with severe reduction of histochemical COX activity (arrows). (D) Perls staining demonstrating punctuate accumulation of 
iron in the patient’s muscle fibres. Inset is a positive control (spleen) for the Prussian blue reaction. Bars correspond to 100 µm.
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a de novo event (figure 2C, online supplementary figure S2): the 
parental DNA samples were analysed also by deep sequencing to 
exclude very low level of the variant, suggestive of germinal mosa-
icism. All the ISCU coding regions were well covered by WES. We 
then screened our patient and his parents for the intronic region 
encompassing the common mutation present in all the previously 
described ISCU mutant patients but no variant was identified.
To exclude that WES could have missed the presence of 
another deep intronic variant affecting the splicing or a ‘non-ex-
onic’ variant impairing mRNA transcription/stability, we further 
investigated patient’s specimen at the transcriptional level. No 
aberrant mRNA ISCU species was observed in PCR products 
obtained from fibroblast RNA, and their sequencing showed a 
biallelic expression, suggested by the presence of overlapping 
peaks corresponding to G and T nucleotides in position c.287 
(online supplementary figure S2).
characterisation of patient’s fibroblasts
The amount of ISCU protein in patient’s fibroblasts was similar 
to controls, indicating that the mutant protein is normally synthe-
sised, imported into mitochondria and stable (figure 2D). In line 
with previous reports showing that the biochemical phenotype 
associated with mutant ISCU is very much attenuated, fibroblasts 
harbouring the ISCUG96V mutation showed hardly any defect in 
activities or protein amounts for a number of mitochondrial 
Fe-S dependent enzymes including mACO, LIAS (as indicated 
by the presence of lipoate cofactor (Lip) on pyruvate and keto-
glutarate dehydrogenase E2 subunits), ferrochelatase and respi-
ratory chain complexes I, II and III (online supplementary figure 
S3A–F). A minor defect was observed in complex IV, in line with 
the muscle biopsy analyses, and in the activity of cytosolic aconi-
tase (IRP1). Analysis of steady-state levels of cytosolic/nuclear 
Fe-S proteins as a measure for maturation-dependent stability 
Figure 2 Identification and characterisation of an ISCU mutation. (A) Schematic representation of the ISCU cDNA (NM_213595.2) and ISCU protein with 
the nucleotide/amino acid change identified in this study. The functional IscU-like domain is in red; the mitochondrial targeting sequence (MTS) is in yellow. 
(B) Phylogenetic conservation of the amino acid residue (Gly96, in green) affected by the missense mutation identified in the patient. (C) electropherograms 
of the genomic region (gDNA) and transcript (cDNA) harbouring the ISCU mutation, and pedigree. (D) Immunoblot analysis of ISCUG96V mutant protein 
expression and subcellular localisation. Control and patient fibroblasts were harvested by trypsination, permeabilised by digitonin treatment, and separated 
into a cytosolic and a mitochondria-containing membrane fraction. Total cell lysates as well as cytosolic and crude mitochondrial fractions were subjected 
to sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGe) and analysed for ISCU and ATP synthase F1β subunit (mitochondrial marker) 
steady-state protein levels (left panel). Chemiluminescence signals of ISCU and F1β in total lysate samples were quantified, and values obtained from 
patient fibroblasts were expressed relative to control cells (right panel). error bars indicate the SDs (n=3). UTr, untranslated region.
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revealed no general alteration of their cellular abundance (online 
supplementary figure S3G-H). However, we observed a severe 
deficiency of the base-excision DNA repair enzyme NTHL1, a 
[4Fe-4S] protein, and a slight decrease in protein levels of the 
CIA factor IOP1 containing 2 [4Fe-4S] clusters. Taken together, 
our analyses indicate that the presence of the ISCUG96V muta-
tion does not have a strong impact on Fe-S cluster assembly in 
patient’s cultured fibroblasts.
Yeast model
To assess the pathogenic role of the substitution p.Gly96Val 
identified in the patient, we performed studies in a yeast model, 
by introducing the analogous amino acid substitution (G97V) in 
the Saccharomyces cerevisiae orthologue of ISCU, the yeast gene 
ISU1. ISU1 has a paralogue, ISU2, arising from a recent gene 
duplication. The double deletion mutant isu1Δisu2Δ is unviable, 
thus indicating the essential role of these proteins in the biogen-
esis of Fe-S clusters, which is in turn indispensable for yeast cell 
survival.34 The double deletion mutant isu1Δisu2Δ, harbouring 
the centromeric pFL38 plasmid (URA3 marker) with the wild-
type (wt) ISU1 to allow viability, was additionally transformed 
with pFL39 centromeric plasmids (TRP1 marker) containing 
either the mutant allele isu1G97V, a wt copy of ISU1, or no gene.
The different strains were plated on 5-fluoroorotic acid 
containing medium to select for cells that have lost the pFL38/ISU1 
plasmid. The strain expressing isu1G97V as the sole ISU1 gene was 
able to grow on glucose at rates similar to strains carrying the wt 
ISU1, while the empty pFL39 did not support growth (figure 3A). 
This result indicates that glycine 97 is not essential for the function 
of the Isu1 protein. However, growth of the strain expressing the 
isu1G97V variant was severely retarded on non-fermentable carbon 
sources (figure 3A), highlighting a deleterious effect of the G97V 
mutation on mitochondrial function.
To test whether the G97V mutation acts as a dominant trait, 
the isu1Δisu2Δ/isu1G97V and the isu1Δisu2Δ/ISU1 strains were 
transformed with either the pGL38 empty vector (as a control) 
or pFL38/ISU1 thus obtaining the heteroallelic strain isu1Δi-
su2Δ/ISU1/isu1G97V and the homoallelic strain isu1Δisu2Δ/I-
SU1/ISU1. Growth on non-fermentable carbon sources was 
clearly reduced in the heteroallelic strain compared with the 
homoallelic wt strain, and also to the strain transformed with 
the empty vector and expressing a single copy of ISU1 (isu1Δi-
su2Δ/ISU1). These results indicate that the G97V mutation 
behaves as dominant (figure 3B). The measurement of the cell 
yield in liquid cultures confirmed what observed in the spot 
assay analysis (figure 3C).
Figure 3 Growth analysis of mutant yeast strains. (A) The strain isu1Δisu2Δ harbouring plasmid pFl39 with the wild-type ISU1 gene or the mutant allele 
isu1G97V was analysed for growth on various media. equal amounts of serial dilutions of cells from exponentially grown cultures were spotted onto yeast 
nitrogen base (YNB) medium plus 2% glucose, 2% lactate or 2% glycerol. The growth was scored after 3 days of incubation at 28°C. (B) The strains 
isu1Δisu2Δ/ISU1 and isu1Δisu2Δ/isu1G97V were transformed with pFl38/ISU1 or with the empty vector. equal amounts of serial dilutions of cells from 
exponentially grown cultures were analysed for growth on YNB medium plus 2% glucose or 2% lactate after 4 days of incubation at 28°C. (C) Cell yield was 
calculated by growing cells on liquid medium containing glucose or lactate and measuring the optical density at 600 nm after 72 hours of growth. error bars 
indicate the SDs (n=3).
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To investigate if the G97V mutation affects mitochondrial Fe-S 
protein biogenesis, we measured the biochemical activities of two 
Fe-S cluster-containing enzymes: aconitase and complex II. These 
activities were reduced in both the isu1Δisu2Δ/isu1G97V and the 
heteroallelic strain isu1Δisu2Δ/ISU1/isu1G97V (figure 4A and B) 
indicating an impairment in Fe-S cluster biogenesis in isu1G97V-con-
taining yeast cells. The activity of complex IV which contains two 
heme centres was also partially reduced (figure 4C). Finally, we 
evaluated the cellular iron content by a colorimetric assay and 
found a twofold increase in the mutant compared with wt strain 
(figure 4D) consistent with a defective core ISC machinery.35
To further investigate the impact of the G97V mutation on 
Isu1 function, we measured the ability of mutant versus wt 
Isu1 protein to assemble a Fe-S cluster in vivo.36 To this end, 
we used the strain Gal-ISU1/isu2Δ, in which ISU2 is deleted 
and ISU1 is under the control of the GAL1-10 promoter. The 
levels of Isu1 can be downregulated by growing the cells in the 
presence of glucose.37 Gal-ISU1/isu2Δ cells were transformed 
with pRS426-TDH3 vectors encoding Myc-tagged ISU1wt or 
isu1G97V. To estimate Fe-S cluster binding of Isu1, cells were 
radiolabelled with 55Fe, and the incorporation of radioactivity 
into Isu1G97V or Isu1wt was measured by immunoprecipitation 
and scintillation counting (figure 4E,F). As shown in figure 4F 
(darker bars), the mutant protein showed a 30% reduction in 
the 55Fe binding capacity; this reduction is consistent with the 
mutant growth defect displayed on respiratory carbon sources. A 
decrease was also evident when isu1G97V was expressed in isu1Δ 
cells or when Gal-ISU1/isu2Δ cells were depleted by growth in 
galactose-containing medium, conditions in which endogenous 
wt Isu1 and Isu2 are present, thus mimicking the heteroallelic 
condition (figure 4F, light grey bars, and figure 4E). This result 
showed that the Isu1G97V mutant protein is slightly impaired 
in its ability to incorporate Fe into Fe-S clusters in vivo. The 
alterations observed in mutant strains were not due to a reduced 
Figure 4 Measurement of enzyme activities and iron content in yeast. (A) Aconitase activity was measured in whole-cell extracts from cells grown 
exponentially at 28°C in yeast nitrogen base (YNB) medium plus 0.6% glucose. (B and C) Succinate dehydrogenase activity and cytocrome c oxidase 
activities were measured in a mitochondria-enriched fraction obtained from cells grown as described before. The values for isu1Δisu2Δ/isu1G97V and 
isu1Δisu2Δ/ISU1/isu1G97V strains are expressed as percentage of the activities obtained in the strains isu1Δisu2Δ/ISU1 and isu1Δisu2Δ/ISU1/ISU1. (D) 
Cellular iron content was quantified in cells grown up to early stationary phase in YNB 0.2% glucose and 2% galactose medium. *<0.05 (unpaired two-
tailed t-test), **<0.01 (unpaired two-tailed t-test). (e) Gal-ISU1/isu2Δ cells and isu1Δ cells expressing Myc-tagged Isu1 were radiolabelled with 55Fe 
and 55Fe incorporation into Isu1-Myc was determined by immunoprecipitation with α-Myc antibodies followed by scintillation counting. Wild-type cells 
harbouring the empty vector (e.v.) served as control. Isu1-myc protein levels in isu1Δ cells were determined by immunostaining with α-Myc antibodies. Porin 
(Por1) served as a loading control. (F) Gal-ISU1/isu2Δ cells expressing Isu1 from vector pFl39 and the reporter plasmid pFeT3-GFP were cultivated in SD 
or SGal medium supplemented with 50 µM ferric ammonium citrate. At an optical density=0.5, the GFP-specific fluorescence emission of whole cells was 
determined. error bars indicate the SDs (n=3).
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amount of the mutant Isu1G97V protein since its abundance was 
similar to the wt form (figure 4E). Furthermore, Gal-ISU1/isu2Δ 
cells expressing isu1G97V from vector pFL39 displayed a twofold 
increase of the iron-dependent FET3 promoter on both glucose 
and galactose-containing medium (online supplementary figure 
S4). A deregulated iron homeostasis is a hallmark of cells with 
defective core ISC machinery and explains the increased iron 
levels in cells expressing isu1G97V.
In silico pathogenicity prediction and structural modelling
In silico predictions, by using different tools, were used to eval-
uate the potential effect of the Gly96Val substitution on ISCU 
structure and interaction with its protein partners. ISCU inter-
acts with NFS1, yet the 3D structure of the human NFS1-ISCU 
complex is hitherto unknown. Instead, we used the reported 
crystal structure of the E. coli IscS-IscU complex formed by 
an IscS dimer which binds two IscU at opposite ends of IscS.38 
Notably a similar, yet unusual monomeric structure has been 
recently described for the IscS human orthologue NFS1.39 
Human Gly96 which corresponds to Gly64 in E. coli
38 is located 
in a flexible loop, at the beginning of the helix α1, next to the 
potential Fe-S cluster-co-ordinating Cys95 residue (Cys63 in E. 
coli).40 We analysed the possible interactions of Gly64 with IscS/
NFS1 by using First Glance in Jmol. The glycine backbone could 
establish hydrophobic interaction with IscS Met315 that is located 
inside a stretch (YVEGESLLMAL) highly conserved from E. coli 
to human. Although both glycine and valine are hydrophobic 
residues, the greater steric hindrance of the valine side chain 
could interfere with the IscS-IscU interaction (figure 5A). More-
over, the loop encompassing residues 62–64 (GCG) of IscU is 
opposite to Glu311 and Ser312 on IscS, and we suggest that the 
valine slightly disturbs these hydrophilic residues (figure 5A). 
The substitution Gly96Val could therefore prevent the correct 
orientation of the adjacent cysteine side chain, thus interfering 
with the Fe co-ordination and explaining the defective ISCU 
function (figure 5B).
dIscussIon
ISCU (Isu1-2 in yeast) is an essential scaffold protein for the 
biosynthesis of Fe-S clusters. Recessive hypomorphic ISCU alleles 
have been associated with isolated myopathy11 12 or skeletal and 
cardiac myopathy14 in humans. Here, we report a heterozygous, 
de novo dominant ISCU variant, G96V, causing congenital myop-
athy in a single patient. The following considerations provide 
evidence that this variant exerts a deleterious, dominant effect 
on Fe-S-dependent enzyme activities. First, we observed striking 
clinical, histological, histochemical and biochemical abnormal-
ities affecting skeletal muscle, which define a mitochondrial 
Figure 5 In silico structural analysis. (A) ribbon diagram of the Escherichia coli IscS (coloured in grey)-IscU (coloured in orange) complex (PDB ID: 3lvl). 
Close view of the Gly64 of IscU and Glu311, Ser312 and Met315 of IscS represented in Van der Waals and coloured by type. (B) residues supposed to be 
involved in the co-ordination of the 2Fe-2S are represented as sticks.
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myopathy similar to that reported in ISCU recessive mutations, 
including partial depletion of SDH and COX histochemical 
reactions, generalised reduction of the MRC complex activities, 
and accumulation of iron deposits. Similar to recessive ISCU 
cases, our patient displayed isolated myopathy with fluctuating, 
waxing and weaning episodes of profound muscle weakness, 
in the context of a congenital myopathy with moderately high 
CK and no involvement of extramuscular organs, including the 
CNS. Second, the mutation was absent in both healthy parents, 
supporting its sporadic occurrence in the proband, and was the 
only gene defect related to mitochondrial myopathies identified 
by WES. Third, analysis of the corresponding genetic defect 
in yeast suggested a Fe-S protein biogenesis defect, including 
defects in OXPHOS and the cellular iron regulon. The effects 
were dominant, since both the monoallelic and the heteroallelic 
genotypes were associated with the phenotype.
While our yeast studies suggest that Isu1G97V is function-
ally impaired by itself, what might then be the reason for the 
observed dominance of both the human ISCUG96V and corre-
sponding yeast Isu1G97V mutations? ISCU, as the scaffold protein 
for the de novo synthesis of Fe-S clusters within mitochon-
dria, interacts with a number of other ISC proteins during Fe-S 
biosynthesis, although the stoichiometry of these interactions 
is controversial. Similar to the bacterial structure, the mamma-
lian ISC complex was proposed to be composed of two NFS1 
and two ISCU subunits,4 41 with a central NFS1 dimer and two 
molecules of ISCU at each end of the NFS1 dimer. Recently, 
a [FXN42–210]24-[NFS1]24-[ISD11]24-(ISCU)24 complex model 
was proposed,40 but it was obtained by overexpressing human 
proteins in E. coli and it is probably not relevant in vivo. We 
think that the functional impairment of ISCU by the G96V 
mutation may be caused by structural changes, as suggested 
by our in silico analyses. For instance, the orientation of the 
potential Fe-S cluster-co-ordinating Cys95 adjacent to Gly96 
could be altered by replacement of the helix-breaking glycine 
residue, with a negative outcome on protein function in Fe-S 
cluster assembly. Moreover, the mutated protein structure may 
become stiffer, thus negatively affecting the interactions with its 
other partner ISC proteins, notably NFS1. The altered interac-
tion between NFS1 and the mutant ISCU could in turn affect 
the assembly/function of the entire ISC biosynthetic complex. 
In support of this view stands the observation that the ISCUG96V 
mutant protein is stable and not degraded, and its amount is 
similar to that of ISCUwt in patient’s fibroblasts. In addition, the 
dominant effect may be caused by the intermediate formation of 
an ISCU holodimer which, according to in vitro reconstitution 
studies, is the product of the ISC biosynthetic complex.5 42 In the 
homodimer, the mutated Gly96 residue in one ISCU monomer 
would likely directly face the other wt ISCU monomer because 
of the bridging character of [2Fe-2S] cluster binding. This could 
lead to the observed dominant negative effect of the mutated 
ISCU on wt ISCU proteins. This might also be the reason why 
we observed less radiolabelled 55Fe bound to yeast Isu1G97Vcom-
pared with the wt protein. Interestingly, the dominant-negative 
behaviour of the G97V mutation differs from the recessive effect 
reported for the G50E mutation in both yeast and humans, 
which can be ascribed to haploinsufficiency of the G50E allele.43
Although ubiquitous, the ISCUG96V variant produces a clinically 
detectable effect only in one critical tissue, skeletal muscle, in line 
with the purely myopathic presentation of the common ISCUIV-
S5+382G>C splicing variant already reported in Swedish patients. 
Similar to our results, no evident mitochondrial phenotype in 
fibroblasts has been previously reported in cases with ISCU-re-
lated recessive disease.14 44–46 The molecular mechanisms that 
make skeletal muscle exquisitely sensitive to partial ISCU impair-
ment warrant further investigation in patient-derived cells and, 
possibly, animal models. A tissue-specific splicing of ISCU was 
proposed for the common ISCUIVS5+382G>C mutation to explain 
the skeletal muscle phenotype,13 but this hypothesis cannot be 
applied for either the p.G96V or the p.G50E missense variants, 
which are equally associated with muscle-specific dysfunction. 
The structural alterations and impaired interactions with partner 
proteins caused by the p.G96V could have tissue-specific effects 
which explain the muscle involvement. A greater sensitivity of 
ISCU-mutant myoblasts to oxidative stress,45 and exercise-in-
duced oxidative damages in muscle,47 may also account for the 
muscular phenotype. Nevertheless, tissue specificities for many 
of the mitochondrial diseases due to defective nuclear-encoded 
genes with housekeeping functions are currently poorly under-
stood and hardly predictable.
The multiple biochemical defects of MRC activities observed 
in our patient were expected for complexes I, II and III which 
contain Fe-S clusters. A defect was also seen for the Fe-S clus-
ter-free complex IV, which harbours Cu2+ and Fe-containing 
heme a/a3 as redox centres. In principle, this may be due to a 
defect in the Fe-S protein ferrochelatase catalysing the last step 
of heme biosynthesis.48 However, strong complex IV defects are 
also seen on depletion of ISCA1, ISCA2 and IBA57 in both human 
and yeast cells.49 50 These ISC proteins are specific for mitochon-
drial [4Fe-4S] protein maturation, yet are not involved in the 
assembly of the [2Fe-2S] cluster on human ferrochelatase. More-
over, we observed a complex IV impairment in the mutant yeast 
model despite the yeast orthologue enzyme is devoid of a Fe-S 
cluster. Nevertheless, complex IV defects are common secondary 
effects of an impairment of Fe-S protein biogenesis.6 49 A complex 
IV deficiency (19%–28% residual activity) was also reported 
in the two siblings with the most severe ISCU-related pheno-
type, and a partial reduction was found in five subjects with the 
Swedish-type myopathy.14 This may be due to a downstream 
damaging effect linked to impairment of complexes I, II and 
III or to the hampered formation of MRC supercomplexes. In 
addition to the biochemical defects, the histochemical analysis 
was peculiar, with a quite specific pattern of SDH and COX 
deficiency; this was suggested to be a pathognomonic finding of 
a myopathy related to Fe-S cluster.9 However, in patients with 
mutations in FXN, the picture is different, with mainly COX 
negative fibres and nearly normal SDH staining.51 Other Fe-S 
diseases are rare and usually present as neurological disorders 
with minimal myopathic signs, while little is known about their 
muscle features. Collectively, the histochemical pattern in muscle 
biopsy seems specific for ISCU myopathy.
In conclusion, we report the first heterozygous dominant muta-
tion in ISCU; notably, this alteration resulted in a similar phenotype 
as the recessive ISCU disease previously described. Our finding 
stresses the importance of a deep analysis of WES data that may 
include, for sporadic cases, any mode of transmission. Moreover, 
our study confirms that recessive and dominant mutations in the 
same gene may lead to the same disease, as already reported for 
other mitochondrial disorders (eg, DNM1L mutations).
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